MEPDF (Medipal Holdings) NonCurrent Deferred Revenue: $0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEPDF Medipal Holdings Corp MEPDF
81 GF Score
Price $18.35
GF Value $17.73
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Medipal Holdings NonCurrent Deferred Revenue?

Medipal Holdings MEPDF 81 NonCurrent Deferred Revenue is $0 Mil as of Mar. 2026. GuruFocus rates MEPDF with a GF Score™ of 81/100 and a GF Value™ of $17.73 (Fairly Valued). The stock has 3 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Medipal Holdings's non-current deferred revenue for the quarter that ended in Mar. 2026 was $0 Mil.

Medipal Holdings NonCurrent Deferred Revenue Related Terms

Medipal Holdings NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Medipal Holdings's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medipal Holdings NonCurrent Deferred Revenue Chart

Medipal Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medipal Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEPDF
81GF Score
Medipal Holdings Corp MEPDF
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0 Mil mean?
Medipal Holdings (MEPDF) has a NonCurrent Deferred Revenue of $0 Mil as of Mar. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Medipal Holdings and its competitors.
Is Medipal Holdings' NonCurrent Deferred Revenue too high?
Medipal Holdings' current NonCurrent Deferred Revenue is $0 Mil. Overall, Medipal Holdings has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' NonCurrent Deferred Revenue compare to MCK and COR?
Medipal Holdings' NonCurrent Deferred Revenue of $0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Distribution company?
A good NonCurrent Deferred Revenue depends on the Medical Distribution industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Medipal Holdings and its competitors. Medipal Holdings's current NonCurrent Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MEPDF) is currently considered Fairly Valued. The stock's GF Value™ is $17.73, compared to a current price of $18.35 — trading 3.5% above its estimated fair value. The current NonCurrent Deferred Revenue is $0 Mil. Medipal Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current NonCurrent Deferred Revenue is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medipal Holdings (MEPDF) Overvalued in 2026?

Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued. The current stock price of $18.35 is trading 3.5% above its estimated GF Value™ of $17.73. GuruFocus considers Medipal Holdings to be Fairly Valued.

Key valuation signals for MEPDF:

  • NonCurrent Deferred Revenue: $0 Mil
  • GF Value™: $17.73 vs. price of $18.35 (3.5% above fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medipal Holdings Business Description

Other Exchanges MAHLY:USA7459:Japan
Address 3-1-1 Kyobashi, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score

Get the complete analysis for MEPDF

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.35
Price
$17.73
GF Value